Locally Advanced NSCLC: Where Are We, Where Do We Go From Here?

Overview

This webinar will provide an updated overview of current standard therapies for stage III NSCLC.  It will also review the most recent data and current trials likely to impact standards of care.  

Program Objectives:

  • Increase clinician awareness of novel immunotherapeutic and targeted biologic agents that have demonstrated activity in stage IV NSCLC and may be appropriate candidates for clinical trials in earlier stages of disease.
  • Review current management of stage III NSCLC, including combined modality approaches and the potential use of immunotherapy, or targeted biologic agents.
  • Identify ongoing clinical trials that are likely to impact patient care in the near future.

 

 

Date
May 09, 2017 -
May 09, 2017
Location

Online

After viewing this program, attendees will:

  • have a better understanding of current data supporting standard chemoradiotherapy regimens for locally advanced NSCLC.
  • be able to discuss the rationale for clinical trials evaluating the integration of immunotherapies into standard treatment paradigms.
  • have an awareness of the preliminary data emerging from combined modality trials incorporating immunotherapy for stage III NSCLC.
  • be able to address the use of targeted therapies in the setting of stage locally advanced disease.

Everett E. Vokes, MD
John E. Ultmann Professor, Chairman, Department of Medicine, Physician-in-Chief, University of Chicago, Medicine and Biological Sciences.

Program Chair-Ramaswamy Govindan, MD
Co-Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.

For any inquiries, please contact meetings@iaslc.org.

After viewing this program, attendees will:

  • have a better understanding of current data supporting standard chemoradiotherapy regimens for locally advanced NSCLC.
  • be able to discuss the rationale for clinical trials evaluating the integration of immunotherapies into standard treatment paradigms.
  • have an awareness of the preliminary data emerging from combined modality trials incorporating immunotherapy for stage III NSCLC.
  • be able to address the use of targeted therapies in the setting of stage locally advanced disease.

Everett E. Vokes, MD
John E. Ultmann Professor, Chairman, Department of Medicine, Physician-in-Chief, University of Chicago, Medicine and Biological Sciences.

Program Chair-Ramaswamy Govindan, MD
Co-Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.

For any inquiries, please contact meetings@iaslc.org.

Share